Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7135451 | 0.99 | DRD2 (0.47) | DRD2HTR2AADRA1ADRD3SRC | |
| Hydrochloric Acid SCHEMBL6731224 | 0.98 | DRD2 (0.47) | DRD2HTR2AADRA1ADRD3SRC | |
| SCHEMBL6741310 | 0.96 | DRD2 (0.45) | DRD2HTR2AADRA1ADRD3SRC | |
| Hydrochloric Acid SCHEMBL6740776 | 0.95 | DRD2 (0.44) | DRD2HTR2AADRA1ADRD3KCNH2 | |
| Ensaculin SCHEMBL677971 | 0.86 | HTR2A (0.63) | DRD2HTR2AADRA1AKCNH2 | |
| Ensaculin SCHEMBL29722503 | 0.86 | HTR2A (0.63) | DRD2HTR2AADRA1AKCNH2 | |
| SCHEMBL17343106 | 0.85 | ALDH1A1 (0.58) | DRD2HTR2AADRA1ADRD3KCNH2 | |
| SCHEMBL6739040 | 0.82 | HTR7 (0.50) | DRD2HTR2AADRA1ADRD3KCNH2 | |
| SCHEMBL8805913 | 0.81 | DRD2 (0.71) | DRD2HTR2AADRA1ADRD3ABCB1 | |
| Hydrochloric Acid SCHEMBL6952251 | 0.81 | HTR7 (0.49) | DRD2HTR2AADRA1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014768-A1 | Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1receptors and/or dopamine d2 receptors | MERCK PATENT GMBH (DE) | 2004-01-22 | — | — | US | disclosed |
| EP-1311503-A1 | CHROMENONE DERIVATIVES AND THEIR USE FOR TREATING DISEASES IN CONJUNCTION WITH 5-HTA1 RECEPTORS AND/OR DOPAMINE D2 RECEPTORS | MERCK PATENT GmbH (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016354-A1 | CHROMENONE DERIVATIVES AND THEIR USE FOR TREATING DISEASES IN CONJUNCTION WITH 5-HTA1 RECEPTORS AND/OR DOPAMINE D2 RECEPTORS | MERCK PATENT GMBH (DE) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014768-A1 | Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1receptors and/or dopamine d2 receptors | HTR1A, HTR1D, HTR1E | DRD2 43/4885HTR2A 12/4885ADRA1A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.